10.07.2018
SHOP APOTHEKE EUROPE N.V. NL0012044747
DGAP-News: SHOP APOTHEKE EUROPE continues its accelerated growth course. Consolidated revenues more than doubled to EUR 257 million during the first half of 2018.
DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): Preliminary Results/Half
Year Results
SHOP APOTHEKE EUROPE continues its accelerated growth course. Consolidated
revenues more than doubled to EUR 257 million during the first half of 2018.
10.07.2018 / 07:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
NOT FOR RELEASE OR DISTRIBUTION IN THE USA, CANADA, AUSTRALIA OR JAPAN.
SHOP APOTHEKE EUROPE continues its accelerated growth course.
Consolidated revenues more than doubled to EUR 257 million during the first
half of 2018.
* Increase of over 120 % to ca. EUR 202 million in German core market.
* International revenues rose by 61% to around EUR 55 million.
Venlo, the Netherlands, July 10, 2018. SHOP APOTHEKE EUROPE N.V., Europe's
leading online pharmacy, continued to post strong growth during the first
half of 2018. According to preliminary calculations group revenues increased
by +103% to more than EUR 257 million compared to EUR 127 million for the
first half of last year.
Organic growth and the consolidation of Europa Apotheek, which the company
had acquired last year, led to a significant revenue boost in Germany. As a
result SHOP APOTHEKE EUROPE increased its half-year revenues in Continental
Europe's largest online pharmacy market by more than 120% to EUR 202 million
compared to the same period last year (first half 2017: EUR 92 million).
SHOP APOTHEKE EUROPE also continues to grow strongly in its international
markets - Austria, Belgium, France, Italy, Spain and the Netherlands.
Revenues for the "International" segment rose by EUR 21 million, from EUR 34
million to EUR 55 million, which is equivalent to a growth rate of more than
61%.
SHOP APOTHEKE EUROPE will publish the full half-year report as planned on
August 14, 2018.
ABOUT SHOP APOTHEKE EUROPE.
SHOP APOTHEKE EUROPE is the leading and fastest growing online pharmacy in
Continental Europe. With the acquisition of Europa Apotheek Venlo in
November 2017, SHOP APOTHEKE EUROPE significantly extended its European
market leadership with an expanded product range for the whole family in the
areas of OTC, beauty and care products as well as prescription drugs.
SHOP APOTHEKE EUROPE already operates online pharmacies in Germany, Austria,
France, Belgium, Italy, Spain and the Netherlands. In Germany, the
TÜV-certified shop-apotheke.com is the market leading. SHOP APOTHEKE EUROPE
delivers a broad range of more than 100,000 original products to over 2.8
million active customers quickly and at attractive prices. In addition, SHOP
APOTHEKE EUROPE provides comprehensive and consistent pharmaceutical
services.
SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the
Frankfurt Stock Exchange (Prime Standard) since 13 October 2016.
MEDIA CONTACTS.
Trade and public media:
Sven Schirmer
Mobile: +49 152 28 50 63 61
Email: [email protected]
Financial media:
Thomas Schnorrenberg
Mobile: +49 151 46 53 13 17
Email: [email protected]
Investor Relations:
Dr. Ulrich Wandel
Telephone: +31 77 850 6117
Email: [email protected]
DISCLAIMER.
This publication is an advertisement. This communication constitutes neither
an offer to sell nor a solicitation to buy securities of Shop Apotheke
Europe N.V. in any jurisdiction. This is not a securities prospectus. No
public offering of any securities of Shop Apotheke Europe N.V. is being
made. Statements contained herein may constitute "forward-looking
statements." Forward-looking statements are generally identifiable by the
use of the words "may", "will", "should", "plan", "expect", "anticipate",
"estimate," "believe", "intend", "project", "goal" or "target" or the
negative of these words or other variations on these words or comparable
terminology. Forward-looking statements are based on current expectations
and involve a number of known and unknown risks, uncertainties and other
factors that could cause the Group's or its industry's actual results,
levels of activity, performance or achievements to be materially different
from any future results, levels of activity, performance or achievements
expressed or implied by such forward-looking statements. You should not
place undue reliance on forward-looking statements and the Group does not
undertake publicly to update or revise any forward-looking statement that
may be made herein, whether as a result of new information, future events or
otherwise.
---------------------------------------------------------------------------
10.07.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: SHOP APOTHEKE EUROPE N.V.
Dirk Hartogweg 14
5928 LV Venlo
Netherlands
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail: [email protected]
Internet: www.shop-apotheke-europe.com
ISIN: NL0012044747, DE000A19Y072
WKN: A2AR94, A19Y07
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
702955 10.07.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
SHOP APOTHEKE EUROPE N.V. ISIN: NL0012044747 können Sie bei EQS abrufen
E-Commerce , A2AR94 , RDC , XETR:RDC